Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Lichen PlanopilarisFrontal Fibrosing Alopecia
Interventions
DRUG

Low-Dose Naltrexone

Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.

Trial Locations (1)

63141

Washington University, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT04409041 - Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia | Biotech Hunter | Biotech Hunter